New hope for Platinum-Resistant ovarian cancer: targeted drug combo enters phase 2 trial
NCT ID NCT03587311
First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times
Summary
This phase 2 trial tests whether combining bevacizumab (a drug that blocks blood vessel growth) with anetumab ravtansine (a targeted therapy) works better than standard paclitaxel chemotherapy for women with ovarian, fallopian tube, or primary peritoneal cancer that no longer responds to platinum-based treatment. About 96 participants will be randomly assigned to one of the two combinations. The main goal is to see which combo delays cancer progression longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bevacizumab (Avastin) and anetumab ravtansine
- What this could lead to
- If successful, this could offer a new treatment option for women with ovarian cancer that no longer responds to platinum-based chemotherapy.
- What could go wrong
- This is a mid-stage trial with only 96 participants, so results may not apply to all patients. The experimental drug may not work better than the standard paclitaxel, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
HaysMed
Hays, Kansas, 67601, United States
-
Mercy Hospital Pittsburg
Pittsburg, Kansas, 66762, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
Salina Regional Health Center
Salina, Kansas, 67401, United States
-
The University of Kansas Cancer Center - Olathe
Olathe, Kansas, 66061, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, 33146, United States
-
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, 33442, United States
-
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida, 33324, United States
-
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
University of Kansas Health System Saint Francis Campus
Topeka, Kansas, 66606, United States
-
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, 66205, United States
-
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22908, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792, United States
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Weisberg Cancer Treatment Center
Farmington Hills, Michigan, 48334, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill target Hard-to-Treat ovarian cancers?
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered immune cells take aim at Hard-to-Treat cancers
- Immune cells retrained to hunt ovarian cancer in new trial
- New drug combo aims to improve ovarian cancer maintenance with fewer dropouts
- New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches